EGFR-mutated lung cancer: a paradigm of molecular oncology-Reference-Cited by-同舟云学术

EGFR-mutated lung cancer: a paradigm of molecular oncology

Published:2010-10-25 Issue:7 Volume:1 Page:497-514
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhang Zhenfeng¹,Stiegler Amy L.²,Boggon Titus J.²,Kobayashi Susumu³,Halmos Balazs¹

Affiliation:

1. Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, New York Presbyterian Hospital- Columbia University Medical Center, New York, NY, USA

2. Department of Pharmacology, Yale School of Medicine, New Haven, CT, USA

3. Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dacomitinib as first-line treatment for patients with EGFR-mutant non-small- cell lung cancer: Real-world data and Insights;2024-07-29

2. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25

3. Anticancer activity of Araguspongine C via inducing apoptosis, and inhibition of oxidative stress, inflammation, and EGFR‐TK in human lung cancer cells: An in vitro and in vivo study;Journal of Biochemical and Molecular Toxicology;2024-07

4. Analysis of EGFR Gene Mutations in Lung Adenocarcinoma in Karamay, Xinjiang;Oncology and Translational Medicine;2023-12-22

5. Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease;Egyptian Pharmaceutical Journal;2023-10